Ekso Bionics Holdings, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stock-based Compensation (Tables)

Stock-based Compensation (Tables)

9 Months Ended

Sep. 30, 2019

Share-based Payment Arrangement [Abstract]

Schedule of Share-based Compensation, Stock Options, Activity

The following table summarizes information about the Company’s stock options outstanding as of September 30, 2019, and activity during the nine months then ended:



	Stock Awards		Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Life (Years)	Aggregate Intrinsic Value
Balance as of December 31, 2018	6,466		$	3.05
Options granted	674		1.45
Options exercised	(186	)	1.23
Options forfeited	(774	)	2.03
Options cancelled	(230	)	4.41
Balance as of September 30, 2019	5,950		$	3.00	7.45	$	1
Vested and expected to vest at September 30, 2019	5,950		$	3.00	7.45	$	1
Exercisable as of September 30, 2019	3,158		$	4.03	6.07	$	1

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions

The per-share fair value of each stock option was determined on the date of grant using the Black-Scholes option pricing model using the following assumptions:



	Three Months Ended September 30,			Nine Months Ended September 30,
	2019	2018		2019		2018
Dividend yield	N/A ⁽¹⁾	—		—		—
Risk-free interest rate	N/A ⁽¹⁾	2.75%-2.99%		2.12	%	2.70%-2.99%
Expected term (in years)	N/A ⁽¹⁾	5-6		6		5-10
Volatility	N/A ⁽¹⁾	106	%	102	%	104	%

⁽¹⁾ Black-Scholes option pricing model assumptions are not applicable for the three months ended September 30, 2019, as there were no stock options granted during this period.

Schedule of Unvested Restricted Stock Units Roll Forward

RSU activity for the nine months ended September 30, 2019 is summarized below:



	Number of Shares		Weighted- Average Grant Date Fair Value
Unvested as of December 31, 2018	278		$	1.83
Granted	560		1.64
Vested	(622	)	1.66
Forfeited	(79	)	1.96
Unvested at September 30, 2019	137		$	1.76

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs

Total stock-based compensation expense related to options and RSUs granted to employees and non-employees is included in the condensed consolidated statements of operations and comprehensive income (loss) as follows:



	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Sales and marketing	$	137	$	171	$	516	$	446
Research and development	57		87		175		312
General and administrative	293		680		989		1,474
	$	487	$	938	$	1,680	$	2,232